[
    [
        {
            "time": "2018-11-02",
            "original_text": "Novartis Injects Itself Into Planned Rollout of EpiPen Competitor",
            "features": {
                "keywords": [
                    "Novartis",
                    "EpiPen",
                    "competitor",
                    "rollout"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Novartis Injects Itself Into Planned Rollout of EpiPen Competitor",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-11-02",
            "original_text": "Novartis to Spin-Off Alcon as Separate Trading Company",
            "features": {
                "keywords": [
                    "Novartis",
                    "Alcon",
                    "spin-off",
                    "trading"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-07-02",
            "original_text": "ADMP Abuzz, MESO Has A Blast, COOL Rebounds, BLFS Up Nearly 150% YTD",
            "features": {
                "keywords": [
                    "ADMP",
                    "MESO",
                    "COOL",
                    "BLFS",
                    "YTD"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotech"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 5,
                "Impact": 6,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-07-02",
            "original_text": "Health Care Sector Update for 07/02/2018: ABBV,PRGO,TEVA,NVS,ADMP,MRK,AZN",
            "features": {
                "keywords": [
                    "Health Care",
                    "Sector",
                    "Update",
                    "ABBV",
                    "PRGO",
                    "TEVA",
                    "NVS",
                    "ADMP",
                    "MRK",
                    "AZN"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-11-02",
            "original_text": "Novartis Securities Investment Ltd -- Moody's downgrades Novartis' rating to A1; stable outlook",
            "features": {
                "keywords": [
                    "Novartis",
                    "Moody's",
                    "downgrades",
                    "rating",
                    "A1",
                    "stable",
                    "outlook"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "finance",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-11-02",
            "original_text": "Adamis Pharma Shares Soar on Deal With Novartis for Epipen Competitor",
            "features": {
                "keywords": [
                    "Adamis",
                    "Pharma",
                    "Shares",
                    "Soar",
                    "Deal",
                    "Novartis",
                    "Epipen",
                    "Competitor"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-11-02",
            "original_text": "Nordstrom may have trouble, Novartis signs distribution deal, Netflix buys LA billboards",
            "features": {
                "keywords": [
                    "Nordstrom",
                    "Novartis",
                    "distribution",
                    "deal",
                    "Netflix",
                    "LA",
                    "billboards"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "retail",
                    "healthcare",
                    "media"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-11-02",
            "original_text": "Gilead's (GILD) CAR T Therapy Gets Positive CHMP Opinion",
            "features": {
                "keywords": [
                    "Gilead",
                    "CAR",
                    "T",
                    "Therapy",
                    "CHMP",
                    "Opinion"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-11-02",
            "original_text": "After a year-long search, Adamis has a partner to market its EpiPen competitor",
            "features": {
                "keywords": [
                    "Adamis",
                    "EpiPen",
                    "competitor",
                    "partner",
                    "market"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-11-02",
            "original_text": "Nordstrom may have trouble according to analyst, Novartis signs distribution deal for EpiPen competitor, Netflix reportedly buys LA billboards",
            "features": {
                "keywords": [
                    "Nordstrom",
                    "analyst",
                    "Novartis",
                    "distribution",
                    "deal",
                    "EpiPen",
                    "competitor",
                    "Netflix",
                    "LA",
                    "billboards"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "retail",
                    "healthcare",
                    "media"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-11-02",
            "original_text": "The Swiss Stock Market Pulled Back On Trade War Concerns",
            "features": {
                "keywords": [
                    "Swiss",
                    "Stock",
                    "Market",
                    "Pulled",
                    "Back",
                    "Trade",
                    "War",
                    "Concerns"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "finance"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 6,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        }
    ]
]